Current Headlines

  1. Scientists Uncover New Method For Developing Tracers Used For Medical Imaging
    6/20/2019

    In an advance for medical imaging, scientists from University of North Carolina Lineberger Comprehensive Cancer Center have discovered a method for creating radioactive tracers to better track pharmaceuticals in the body as well as image diseases, such as cancer, and other medical conditions

  2. Human-On-A-Chip Model Enables Simultaneous Testing Of Cancer Drug Efficacy And Off-Target Toxicity To Enable Determination Of Therapeutic Index
    6/19/2019

    A reconfigurable “body-on-a-chip” model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organs, such as the heart and liver

  3. Ricoh Announces Strategic Business Partnership With Elixirgen Scientific
    6/19/2019

    Ricoh Company, Ltd., (Tokyo, Japan) today announced it has entered into a strategic business partnership with Elixirgen Scientific, Inc., (Baltimore, Maryland, USA), to develop innovative biomedical products and services that support drug discovery based on cell differentiation*1 technology

  4. Gilead And Nurix Establish Strategic Collaboration To Develop Novel Therapies For Cancer And Other Diseases
    6/19/2019

    Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases

  5. Denovo Biopharma Receives Global Rights To A Novel Late-Stage Drug For Alzheimer's Disease From Orion Corporation For Development As A Personalized Medicine
    6/18/2019

    Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has licensed ORM-12741 from Orion Corporation. Denovo gains global rights to develop, manufacture and commercialize ORM-12741

  6. New Drug Compound Could Tackle Major Life-Limiting Kidney Disease
    6/18/2019

    Scientists from the University of Sheffield are part of an international collaboration to develop a new class of drugs to treat a common genetic kidney disease which is a major cause of kidney failure

  7. Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio By Acquiring NexusPharma
    6/18/2019

    Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group® (GBG), announced that it has expanded its drug development services through the acquisition of a majority interest in NexusPharma

  8. Personalized Stem Cells, Inc. Submits Investigational New Drug (IND) Application For The Treatment Of Osteoarthritis With Stem Cells
    6/18/2019

    Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has submitted an Investigational New Drug (IND) application to the FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial uses stem cells as a treatment of osteoarthritis in the knee

  9. Abveris Deploys The Berkeley Lights Beacon Platform For Antibody Discovery
    6/17/2019

    Abveris, Inc., a leader in contract research antibody discovery, recently announced the deployment of the Berkeley Lights, Inc. Beacon optofluidic platform for antibody discovery. Concurrent with this announcement, Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services

  10. BeiGene Regains Full Global Rights To Its Investigational Anti-PD-1 Antibody Tislelizumab
    6/17/2019

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has entered into a mutual agreement with Celgene Corporation to terminate the parties’ global collaboration for tislelizumab, BeiGene’s investigational anti-PD-1 antibody, in advance of the pending acquisition of Celgene by Bristol-Myers Squibb